The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Heparin Inhibition of Selectin-Mediated Interactions during the Hematogenous Phase of Carcinoma Metastasis: Rationale for Clinical Studies in Humans
Abstract
Classic studies indicate that the formation of tumor cell-platelet complexes in the blood stream is important in facilitating the metastatic process. Metastasis in animal models can be inhibited by heparin, and retrospective analyses of heparin use in human cancer have shown promise. However, most follow-up human studies using vitamin K antagonists have failed, and conclusive proof for other previously proposed mechanisms of heparin action is lacking. Carcinoma progression and metastasis are associated with overexpression of sialylated fucosylated mucins. Structurally similar molecules happen to be natural ligands for vascular adhesion molecules called the selectins. Heparin also happens to be a good inhibitor of P-selectin, which is expressed on activated platelets or endothelial cells. We have found that heparin blocks P-selectin-mediated interactions of endogenous platelets with sialylated fucosylated mucins on circulating carcinoma cells and that this reduces tumor cell survival. The use of more specific and selective P-selectin inhibitors will some day help to dissect the relative importance of this mechanism of heparin action in cancer. Meanwhile, we suggest that the failure of vitamin K antagonists to improve cancer prognosis should be ignored and that heparin therapy should be immediately revisited under this new paradigm. Unlike the suggestions in most previous studies, we propose that heparin use should be reexplored specifically during the interval from initial visualization of a primary tumor until just after its definitive surgical removal. A suggested clinical trial is outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selectins and their ligands: Current concepts and controversies
Kansas, G. (1996) · Blood · doi:10.1182/blood.v88.9.3259.bloodjournal8893259 · Cited by 1,415
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“These molecules were called "selectins" (289), and they recognized a common motif, consisting of sialylated fucosylated glycans (7, 13, 24, 91, 103, 128, 140, (290) (291) (292) (293) (294) (295) (296) (297) (298) (299) (300) (301) (302) (303) (304) (305) (306) (307) (308) (309) ; a topic that has continued to blossom,…”
Self-citationThe sweet and sour of cancer: glycans as novel therapeutic targets
Fuster, M. M., & Esko, J. D. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1649 · Cited by 1,383
Sialic acids in human health and disease
Varki, A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.06.002 · Cited by 999
Self-citationGlycan-based interactions involving vertebrate sialic-acid-recognizing proteins
Varki, A. (2007) · Nature · doi:10.1038/nature05816 · Cited by 853
Self-citationTrousseau's syndrome: multiple definitions and multiple mechanisms
Varki, A. (2007) · Blood · doi:10.1182/blood-2006-10-053736 · Cited by 840
Self-citation
Metadata
- Authors
- Varki, N. M., & Varki, A.
- Venue
- Seminars in Thrombosis and Hemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2002
- Volume
- 28
- Issue
- 1
- Pages
- 53-66
- ISSN
- 0094-6176 (ISSN-L)
- 1098-9064
- OpenAlex
- W2140074915
- Cited by
- 163
- References
- 1
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heparin Inhibition of Selectin-Mediated Interactions during the Hematogenous Phase of Carcinoma Metastasis: Rationale for Clinical Studies in Humans. https://app.cochat.ai/papers/10.1055/s-2002-20564
- The paper
- Varki, N. M., & Varki, A. (2002). Heparin Inhibition of Selectin-Mediated Interactions during the Hematogenous Phase of Carcinoma Metastasis: Rationale for Clinical Studies in Humans. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/s-2002-20564
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.